PubMed:32194980 / 1177-1516 JSONTXT

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T43","span":{"begin":36,"end":40},"obj":"CHEBI:23888"},{"id":"T44","span":{"begin":36,"end":40},"obj":"CHEBI:23888"},{"id":"T45","span":{"begin":83,"end":88},"obj":"SP_6"},{"id":"T46","span":{"begin":83,"end":88},"obj":"NCBITaxon:9606"},{"id":"T47","span":{"begin":152,"end":157},"obj":"CHEBI:23888"},{"id":"T48","span":{"begin":152,"end":157},"obj":"CHEBI:23888"},{"id":"T49","span":{"begin":165,"end":174},"obj":"CHEBI:16796"},{"id":"T50","span":{"begin":165,"end":174},"obj":"CHEBI:16796"},{"id":"T51","span":{"begin":176,"end":190},"obj":"CHEBI:50667"},{"id":"T52","span":{"begin":176,"end":190},"obj":"CHEBI:50667"},{"id":"T53","span":{"begin":196,"end":205},"obj":"CHEBI:9168"},{"id":"T54","span":{"begin":196,"end":205},"obj":"CHEBI:9168"},{"id":"T55","span":{"begin":260,"end":264},"obj":"CHEBI:23888"},{"id":"T56","span":{"begin":260,"end":264},"obj":"CHEBI:23888"},{"id":"T57","span":{"begin":265,"end":269},"obj":"SO:0000704"},{"id":"T58","span":{"begin":322,"end":327},"obj":"SP_6"},{"id":"T59","span":{"begin":322,"end":327},"obj":"NCBITaxon:9606"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"Using network proximity analyses of drug targets and HCoV-host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines."}

{"project":"LitCovid-OGER","denotations":[{"id":"T7","span":{"begin":36,"end":40},"obj":"CHEBI:23888"},{"id":"T8","span":{"begin":165,"end":174},"obj":"CHEBI:16796"},{"id":"T9","span":{"begin":176,"end":190},"obj":"CHEBI:50667"},{"id":"T10","span":{"begin":196,"end":205},"obj":"CHEBI:9168"},{"id":"T11","span":{"begin":260,"end":264},"obj":"CHEBI:23888"},{"id":"T4","span":{"begin":58,"end":62},"obj":"GO:0018995"},{"id":"T5","span":{"begin":212,"end":215},"obj":"SO:0001853"},{"id":"T6","span":{"begin":265,"end":269},"obj":"SO:0000704"},{"id":"T7","span":{"begin":270,"end":280},"obj":"SO:0001978"},{"id":"T8","span":{"begin":333,"end":338},"obj":"SO:0000194"}],"namespaces":[{"prefix":"PR","uri":"http://purl.obolibrary.org/obo/PR_"},{"prefix":"UBERON","uri":"http://purl.obolibrary.org/obo/UBERON_"}],"text":"Using network proximity analyses of drug targets and HCoV-host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines."}

{"project":"LitCovid-sentences-v1","denotations":[{"id":"TextSentencer_T8","span":{"begin":0,"end":339},"obj":"Sentence"}],"text":"Using network proximity analyses of drug targets and HCoV-host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines."}

{"project":"LitCovid-TimeML","denotations":[{"id":"tok206","span":{"begin":0,"end":5},"obj":"VBG"},{"id":"tok207","span":{"begin":6,"end":13},"obj":"NN"},{"id":"tok208","span":{"begin":14,"end":23},"obj":"NN"},{"id":"tok209","span":{"begin":24,"end":32},"obj":"NNS"},{"id":"tok210","span":{"begin":33,"end":35},"obj":"IN"},{"id":"tok211","span":{"begin":36,"end":40},"obj":"NN"},{"id":"tok212","span":{"begin":41,"end":48},"obj":"NNS"},{"id":"tok213","span":{"begin":49,"end":52},"obj":"CC"},{"id":"tok214","span":{"begin":53,"end":62},"obj":"NNP"},{"id":"tok215","span":{"begin":63,"end":75},"obj":"NNS"},{"id":"tok216","span":{"begin":76,"end":78},"obj":"IN"},{"id":"tok217","span":{"begin":79,"end":82},"obj":"DT"},{"id":"tok218","span":{"begin":83,"end":88},"obj":"JJ"},{"id":"tok219","span":{"begin":89,"end":100},"obj":"NN"},{"id":"tok220","span":{"begin":100,"end":101},"obj":","},{"id":"tok221","span":{"begin":102,"end":104},"obj":"PRP"},{"id":"tok222","span":{"begin":105,"end":115},"obj":"NN"},{"id":"tok223","span":{"begin":116,"end":118},"obj":"CD"},{"id":"tok224","span":{"begin":119,"end":128},"obj":"JJ"},{"id":"tok225","span":{"begin":129,"end":134},"obj":"NN"},{"id":"tok226","span":{"begin":134,"end":138},"obj":"NNP"},{"id":"tok227","span":{"begin":139,"end":151},"obj":"JJ"},{"id":"tok228","span":{"begin":152,"end":157},"obj":"NNS"},{"id":"tok229","span":{"begin":158,"end":159},"obj":"("},{"id":"tok230","span":{"begin":159,"end":160},"obj":"SYM"},{"id":"tok231","span":{"begin":160,"end":161},"obj":"."},{"id":"tok232","span":{"begin":161,"end":162},"obj":"SYM"},{"id":"tok233","span":{"begin":162,"end":163},"obj":"."},{"id":"tok234","span":{"begin":163,"end":164},"obj":","},{"id":"tok235","span":{"begin":165,"end":174},"obj":"NN"},{"id":"tok236","span":{"begin":174,"end":175},"obj":","},{"id":"tok237","span":{"begin":176,"end":190},"obj":"NN"},{"id":"tok238","span":{"begin":190,"end":191},"obj":","},{"id":"tok239","span":{"begin":192,"end":195},"obj":"CC"},{"id":"tok240","span":{"begin":196,"end":205},"obj":"JJ"},{"id":"tok241","span":{"begin":205,"end":206},"obj":")"},{"id":"tok242","span":{"begin":207,"end":211},"obj":"WDT"},{"id":"tok243","span":{"begin":212,"end":215},"obj":"VBP"},{"id":"tok244","span":{"begin":216,"end":223},"obj":"JJ"},{"id":"tok245","span":{"begin":224,"end":233},"obj":"JJ"},{"id":"tok246","span":{"begin":234,"end":236},"obj":"IN"},{"id":"tok247","span":{"begin":237,"end":247},"obj":"NN"},{"id":"tok248","span":{"begin":248,"end":256},"obj":"NNS"},{"id":"tok249","span":{"begin":257,"end":259},"obj":"IN"},{"id":"tok250","span":{"begin":260,"end":269},"obj":"JJ"},{"id":"tok251","span":{"begin":270,"end":280},"obj":"NNS"},{"id":"tok252","span":{"begin":281,"end":284},"obj":"CC"},{"id":"tok253","span":{"begin":285,"end":297},"obj":"NNP"},{"id":"tok254","span":{"begin":298,"end":313},"obj":"NNS"},{"id":"tok255","span":{"begin":314,"end":318},"obj":"NNS"},{"id":"tok256","span":{"begin":319,"end":321},"obj":"IN"},{"id":"tok257","span":{"begin":322,"end":327},"obj":"JJ"},{"id":"tok258","span":{"begin":328,"end":332},"obj":"NN"},{"id":"tok259","span":{"begin":333,"end":338},"obj":"NNS"},{"id":"tok260","span":{"begin":338,"end":339},"obj":"."},{"id":"lookup23","span":{"begin":76,"end":78},"obj":"country_code"},{"id":"lookup24","span":{"begin":234,"end":236},"obj":"country_code"},{"id":"lookup25","span":{"begin":265,"end":269},"obj":"person_first"},{"id":"lookup26","span":{"begin":319,"end":321},"obj":"country_code"}],"text":"Using network proximity analyses of drug targets and HCoV-host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines."}

{"project":"LitCovid-PD-FMA-UBERON-v1","denotations":[{"id":"T6","span":{"begin":165,"end":174},"obj":"Body_part"},{"id":"T7","span":{"begin":265,"end":269},"obj":"Body_part"},{"id":"T8","span":{"begin":328,"end":332},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma74644"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma74402"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Using network proximity analyses of drug targets and HCoV-host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines."}